title: Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study.
abstract: OBJECTIVE
  Radiation-induced dermatitis is a very common side effect of radiation therapy, and may necessitate interruption of the therapy. There is a substantial lack of evidence-based treatments for this condition. The aim of this study was to investigate the effect of mometasone furoate cream (MMF) on radiation dermatitis in a prospective, double-blind, randomized study.
  
  
  METHODS
  The study comprised 49 patients with node-negative breast cancer. They were operated on with sector resection and scheduled for postoperative radiotherapy using photons with identical radiation qualities and dosage to the breast parenchyma. The patients were randomized to receive either MMF or emollient cream. The cream was applied on the irradiated skin twice a week from the start of radiotherapy until the 12th fraction (24 Gy) and thereafter once daily until 3 weeks after completion of radiation. Both groups additionally received non-blinded emollient cream daily. The intensity of the acute radiation dermatitis was evaluated on a weekly basis regarding erythema and pigmentation, using a reflectance spectrophotometer together with visual scoring of the skin reactions.
  
  
  RESULTS
  MMF in combination with emollient cream treatment significantly decreased acute radiation dermatitis (P=0.0033) compared with emollient cream alone. There was no significant difference in pigmentation between the two groups.
  
  
  CONCLUSIONS
  Adding MMF, a potent topical corticosteroid, to an emollient cream is statistically significantly more effective than emollient cream alone in reducing acute radiation dermatitis.
authors.affiliation: Department of Dermatology, University Hospital, S-751 85, Uppsala, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Boström
authors.forename: H
authors.initials: H
authors.lastname: Lindman
authors.forename: C
authors.initials: C
authors.lastname: Swartling
authors.forename: B
authors.initials: B
authors.lastname: Berne
authors.forename: J
authors.initials: J
authors.lastname: Bergh
mesh_terms: D000208:Acute Disease; D000287:Administration, Topical; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000532:radiotherapy; D004311:Double-Blind Method; D004643:Emollients / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids; D006801:Humans; D008875:Middle Aged; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000627:therapeutic use*; D011855:Radiodermatitis / Q000188:drug therapy* / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects; D016896:Treatment Outcome; D014944:World Health Organization
chemical_list: D000893:Anti-Inflammatory Agents; D004643:Emollients; D005938:Glucocorticoids; D011244:Pregnadienediols; D000068656:Mometasone Furoate